Tanezumab, an investigational subcutaneously-administered, non-opioid treatment, may benefit patients with moderate to severe chronic low back pain (CLBP), according to top-line results from a Phase 3 study.
A task force of regenerative medicine experts has formulated new guidelines for the safe and effective use of biologics in the management of low back pain.
Intradiscal methylene blue injection was not found to alleviate pain in patients with chronic diskogenic low back pain.
Slump stretching may be beneficial to individuals with low back pain, based on very low to moderate quality evidence.
Color Doppler ultrasound may represent an appropriate tool for the diagnosis of sacroiliitis in patients presenting with inflammatory back pain.
There is insufficient evidence supporting an improved effectiveness of combination drug therapy vs mono-drug therapy in the management of low back pain and sciatica.
Regular and prolonged walking was found to be associated with a reduced the risk for low back pain in Koreans age >50.
A two-point estimation task was associated with greater reliability than commonly used approaches for the assessment of sensory dissociation (SEDI) in patients with chronic low back pain.
The addition of a 2-hour patient education sessions to first-line care may not benefit patients with acute low back pain.
Transcranial direct current stimulation of the left dorsal anterior cingulate cortex may be associated with improvements in pain-related function, distress, and depression in patients with chronic low back pain